Bleeding and thrombosis risk matters: How long can we stick to the one-size-fits-all strategy of platelet inhibition?

JACC: Cardiovascular Interventions

Volumn 6, Issue 8, 2013, Pages 864-866

  Sibbing, Dirk ^a   Gross, Lisa ^a   Orban, Martin ^a   Massberg, Steffen ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

bleeding clopidogrel percutaneous coronary intervention prasugrel stent thrombosis therapeutic window

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PRASUGREL; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR ANTAGONIST; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ANTIHYPERTENSIVE THERAPY; BLEEDING; BLEEDING TENDENCY; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; DRUG MONITORING; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; NOTE; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; STENT THROMBOSIS;

BLEEDING; CLOPIDOGREL; PERCUTANEOUS CORONARY INTERVENTION; PRASUGREL; STENT THROMBOSIS; THERAPEUTIC WINDOW;

ACUTE CORONARY SYNDROME; FEMALE; HEMORRHAGE; HUMANS; MALE; PERCUTANEOUS CORONARY INTERVENTION; PIPERAZINES; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; THIOPHENES; TICLOPIDINE;

EID: 84882759392     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2013.06.002     Document Type: Editorial

References (17)

1. P.A. Gurbel, K.P. Bliden, B.L. Hiatt, and C.M. O'Connor Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 2003 2908 2913 (Pubitemid 36736631)
2. L. Bonello, M. Pansieri, and J. Mancini High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes J Am Coll Cardiol 58 2011 467 473
3. G. Ndrepepa, P.B. Berger, and J. Mehilli Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point J Am Coll Cardiol 51 2008 690 697 (Pubitemid 351221218)
4. L. Bonello, U.S. Tantry, R. Marcucci for the Working Group on High On-Treatment Platelet Reactivity Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 56 2010 919 933
5. P.A. Gurbel, R.C. Becker, K.G. Mann, S.R. Steinhubl, and A.D. Michelson Platelet function monitoring in patients with coronary artery disease J Am Coll Cardiol 50 2007 1822 1834 (Pubitemid 350007957)
6. D. Sibbing, S.R. Steinhubl, S. Schulz, A. Schomig, and A. Kastrati Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window J Am Coll Cardiol 56 2010 317 318
7. G. Campo, G. Parrinello, and P. Ferraresi Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome J Am Coll Cardiol 57 2011 2474 2483
8. L. Bonello, J. Mancini, and M. Pansieri Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel J Thromb Haemost 10 2012 1999 2005
9. F. Mangiacapra, G. Patti, and E. Barbato A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study J Am Coll Cardiol Intv 5 2012 281 289
10. P.A. Gurbel, K.P. Bliden, and I.A. Navickas Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events Am Heart J 160 2010 346 354
11. T. Cuisset, C. Grosdidier, and A.D. Loundou Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA (Predictor of Bleedings With Antiplatelet Drugs) study J Am Coll Cardiol Intv 6 2013 854 863
12. S.D. Wiviott, E. Braunwald, C.H. McCabe for the TRITON-TIMI 38 Investigators Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015 (Pubitemid 350106708)
13. J.L. Ferreiro, D. Sibbing, and D.J. Angiolillo Platelet function testing and risk of bleeding complications Thromb Haemost 103 2010 1128 1135
14. J.P. Collet, T. Cuisset, and G. Range ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting N Engl J Med 367 2012 2100 2109
15. M.J. Price, P.B. Berger, P.S. Teirstein for the GRAVITAS Investigators Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 2011 1097 1105
16. D. Trenk, G.W. Stone, and M. Gawaz A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study J Am Coll Cardiol 59 2012 2159 2164
17. L. Wallentin, R.C. Becker, A. Budaj for the PLATO Investigators Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057